Bovie Medical Corp (BVX) 4.22 $BVX 5 Breakout Stocks for

New Post Public Reply Private Reply Replies (0) Message Board

Sep 26, 2016 at 9:20 AM

Bovie Medical Corp (BVX) 4.22 $BVX

5 Breakout Stocks for Excellent Returns
Swarup Gupta - Zacks Investment Research - Fri Sep 16, 9:06AM CDT
Active investors often utilize a breakout investment strategy in the search for strong returns.
BVX: 4.22 (-0.02), FOMX: 10.20 (-0.08), CVGI: 5.66 (+0.01), KIN: 5.15 (-0.03), EXTR: 4.49 (unch)

Bovie Medical (BVX) Catches Eye: Stock Rises by 8.1%
Zacks Equity Research - Zacks Investment Research - Wed Sep 07, 7:00AM CDT
Bovie Medical Corporation (BVX) was a big mover last session, as the company saw its shares rise over 8% on the day.
GWPH: 107.56 (-2.20), BVX: 4.22 (-0.02)

Can Bovie Medical (BVX) Run Higher on Strong Earnings Estimate Revisions?
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:55AM CDT
Bovie Medical (BVX) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision.
BVX: 4.22 (-0.02)

Bovie J-Plasma(R) Precise 360(TM) Handpiece Named 'Innovation of the Year' by the Society of Laparoendoscopic Surgeons (SLS)
BusinessWire - Tue Aug 30, 7:20AM CDT
Bovie Medical (NYSE:BVX), a maker of medical devices and supplies and the developer of J-Plasma(R), a patented new surgical product, announced that the Bovie(R) J-Plasma(R) product extension, branded the Precise 360(TM), has been named an "Innovation of the Year" by The Society of Laparoendoscopic Surgeons (SLS).
BVX: 4.22 (-0.02)

3 Reasons Why Bovie Medical (BVX) is a Great Momentum Stock
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 7:37AM CDT
Bovie Medical Corporation (BVX) is looking especially impressive right now for momentum-oriented investors
BVX: 4.22 (-0.02)

Is Bovie Medical (BVX) a Great Growth Stock?
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 8:43AM CDT
Bovie Medical (BVX) has a favorable Zacks Rank and is a fast-growing stock that is well positioned for future earnings growth
BVX: 4.22 (-0.02)

Medovex Corporation Begins Commercial Production of DenerveX(TM) Pro-40 Generator in Preparation for EU Launch
Marketwired - Wed Aug 24, 7:00AM CDT
ATLANTA, GA--(Marketwired - Aug 24, 2016) - Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that it and its design and manufacturing partner Bovie Medical have commenced commercial production of the Company's DenerveX™ Pro-40 Power Generator as one more step towards the launch in the EU. Bovie Medical is a Florida based world leader in the development and manufacture of electrosurgical products.
MDVX: 1.70 (+0.03), BVX: 4.22 (-0.02)

Bovie Medical (BVX) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 9:43AM CDT
Bovie Medical Corporation (BVX) has been on the move lately as the stock has risen by more than 100% in the past four weeks, and it is currently trading well above its 20-Day SMA
BVX: 4.22 (-0.02)

Bovie Medical Receives FDA 510(k) Clearance for Its 'PlazXact(TM)' Ablator
BusinessWire - Tue Aug 16, 7:00AM CDT
--- Compatible with standard electrosurgical generators -
BVX: 4.22 (-0.02)

Bovie Medical (BVX) in Focus: Stock Jumps 10% in Session
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 7:05AM CDT
Bovie Medical Corporation (BVX) was a big mover last session, as the company saw its shares rise 10% on the day.
BVX: 4.22 (-0.02), LNTH: 8.49 (-0.58)

Bovie Medical Corporation Reports Second Quarter and First Half 2016 Results
BusinessWire - Mon Aug 01, 3:00PM CDT
--Second quarter revenue increased 27.8% year-over-year, driven by strong demand across the Company's product categories
BVX: 4.22 (-0.02)

Investor Calendar Invites You to the Bovie Medical Corporation Second Quarter 2016 Earnings Conference Call and Webcast Live on Monday, August 1, 2016
ACCESSWIRE - Mon Aug 01, 8:00AM CDT
CLEARWATER, FL / ACCESSWIRE / August 1, 2016 / Bovie Medical (NYSE MKT: BVX) will host a conference call and live webcast to discuss the results of the second quarter 2016, to be held Monday, August 1, 2016 at 4:30 PM Eastern Time.
BVX: 4.22 (-0.02)

Bovie Medical Corporation Reports First Quarter 2016 Results
BusinessWire - Wed May 11, 6:00AM CDT
--Total revenue increased 26.9%
BVX: 4.22 (-0.02)

Investor Calendar Invites You to the Bovie Medical Corporation First Quarter 2016 Earnings Conference Call and Webcast Live on Wednesday, May 11, 2016
ACCESSWIRE - Tue May 10, 3:06PM CDT
CLEARWATER, FL / ACCESSWIRE / May 10, 2016 / Bovie Medical (NYSE MKT: BVX) will host a conference call and live webcast to discuss the results of the first quarter 2016, to be held Wednesday, May 11, 2016 at 8:00 AM Eastern Time.
BVX: 4.22 (-0.02)

Bovie Medical Corporation Announces Time Change for First Quarter 2016 Earnings Call
BusinessWire - Mon May 09, 7:00AM CDT
Bovie Medical (BVX), a maker of medical devices and supplies and the developer of J-Plasma(R), a patented new surgical product, today announced that it has changed the time of its first-quarter 2016 earnings conference call to 8:00 a.m. ET on Wednesday, May 11. The call was previously scheduled for Wednesday, May 11, at 8:30 a.m. ET.
BVX: 4.22 (-0.02)

Bovie Medical Corporation to Participate in Drexel Hamilton Micro-Cap Investor Forum
BusinessWire - Wed May 04, 7:00AM CDT
Bovie Medical Corporation ("Bovie" or the "Company"

(NYSE:BVX), a maker of medical devices and supplies and the developer of J-Plasma(R), a patented new surgical product, announced today that Robert L. Gershon, Chief Executive Officer of the Company, and Jay Ewers, Chief Financial Officer, will participate in the Drexel Hamilton Micro Cap Investor Forum on May 12, 2016.
BVX: 4.22 (-0.02)

Bovie Medical Corporation Announces First Quarter 2016 Earnings Call
BusinessWire - Wed Apr 27, 7:00AM CDT
Bovie Medical (BVX), a maker of medical devices and supplies and the developer of J-Plasma(R), a patented new surgical product, today announced that it will issue its financial results for the first quarter ended March 31, 2016 on Wednesday May 11, 2016 before market open.
BVX: 4.22 (-0.02)

Bovie Medical Corporation Announces Launch of J-Plasma(R) Precise 360(TM) and Its Application in Prostate Surgery Procedures
BusinessWire - Wed Apr 20, 7:00AM CDT
Bovie Medical Corporation, a maker of medical devices and supplies, and the developer of J-Plasma(R), a patented new surgical product, today announced the launch of its J-Plasma(R) product extension, branded the Precise 360(TM).
BVX: 4.22 (-0.02)

Bovie Medical Announces Completion of New J-Plasma(R) White Papers
BusinessWire - Mon Jan 11, 7:00AM CST
--- 10 white papers published on J-Plasma(R) to date
BVX: 4.22 (-0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Euroandinos Paita Closes Consent for 2037 Notes

Port Strategy and Financial Implications Terminales Portuarios Euroandinos Paita S.A., nestled in the Peruvian transport sector, has been tight-rope walking through its debt landscape. Announcing a successful consent solicitation on November 13, 2026, they've taken a significant step towards reconfiguring their long-term financing game. This puppet show of paperwork...

IEHP's Wellness Center Launch Faces Delay in California

Unexpected Delay for IEHP's Community Hub Straight outta Rancho Cucamonga, we've got some news that'll have folks in San Bernardino holding their breath a little longer. The Inland Empire Health Plan (or IEHP if you're part of the 1.4 million served by them) had folks pumped for their new Community Wellness Center. But guess what? They had to slam the brakes on the grand...

Perpetua Reports Q3 2026 Results, Progress on Project

A Steady Climb for Perpetua Resources It's like watching a boxer steadily climb the ranks, waiting for the big title fight. That's the scene with Perpetua Resources (NASDAQ:PPTA) as their Q3 2026 financial results hit the wires. No confetti cannons this time, just solid, gritty steps towards a promising future. Q3 Financial Results: A Prudent Path The financials for...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

ManuTech Center Set to Revolutionize Manufacturing Hub

Jackson's Next Manufacturing Frontier Well, the folks down in Jackson, Michigan, are prepping to cut the red ribbon on something that's got me leaning forward in my seat. The Advanced Manufacturing Training Center (AMTC) is pulling out all the stops with their new ManuTech Prototyping Center. Yup, this center is about to become the playground for startups, manufacturers,...

Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

WeFetch AI: A New Era in Barcode Precision

By Logan Wright Updated Nov 13, 2026 Category News Views 201

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...